Efalizumab in Psoriasis: Our Experience with 11 Patients
نویسنده
چکیده
This is an observational, longitudinal and retrospective study of a group of patients with moderate to severe plaque psoriasis whom had been treated with efaluzimab (1mg/Kg/week) for up to 20 weeks. Nevertheless, first dose of 0.7 mg/kg was given. The efficacy of the drug was evaluated by measuring the psoriasis area and severity index (PASI), the body surface area (BSA) and index of the quality of life (DLQI). A statically significant improvement was observed in the PASI, BSA and DLQI after 4, 12 and 20 weeks of therapy. After 20 weeks of treatment, the PASI 75 and 90 values were 100% and 97% respectively. When it comes to safety, efaluzimab was well tolerated and no remarkable side effects were recorded.
منابع مشابه
[Clinical outcomes in patients with psoriasis following discontinuation of efalizumab due to suspension of marketing authorization].
INTRODUCTION In February 2009, the European Medicines Agency suspended the marketing authorization for efalizumab after 3 confirmed cases of progressive multifocal leukoencephalopathy were reported. To assess the consequences of this decision, we performed a prospective follow-up study of patients in our department who were being treated with efalizumab at the time and compared clinical outcome...
متن کاملEfalizumab-induced severe thrombocytopenia can be resolved
Efalizumab is a monoclonal a humanized recombinant IgG1 monoclonal antibody which targets the CD11a, the alpha-subunit of LFA-1 (lymphocyte function-associated antigen-1). It acts by blocking the T-lymphocyte pathogenetic mechanisms of psoriasis. Thrombocytopenia is an adverse event that occurs during therapy. Thrombocytopenia can be mild and can occur quite early during treatment, together wit...
متن کاملImpact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]
BACKGROUND Chronic psoriasis can negatively affect patients' lives. Assessing the impact of treatment on different aspects of a patient's health-related quality of life (HRQOL) is therefore important and relevant in trials of anti-psoriasis agents. The recombinant humanized IgG1 monoclonal antibody efalizumab targets multiple T-cell-dependent steps in the immunopathogenesis of psoriasis. Efaliz...
متن کاملEfficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
OBJECTIVES: To evaluate the efficacy and safety of efalizumab in continuous or interrupted therapy of adults with moderate-to-severe plaque psoriasis who had failed to respond to or were intolerant of other systemic therapies, including methotrexate, ciclosporin and psoralen plus UVA phototherapy, or for whom such therapies were contraindicated. METHODS: Patients received a conditioning dose of...
متن کاملPsoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series
BACKGROUND Severe psoriasis vulgaris can be extremely difficult to treat in some patients, even with the newer biological therapies available today. CASE PRESENTATIONS We present two patients with severe chronic plaque psoriasis who received numerous systemic anti-psoriatic therapies with varied results. Both responded well to initial treatment with efalizumab (anti-CD11a), but then experienc...
متن کامل